A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
An Almost Normal Life Expectancy for People With HIV?
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Misleading News Reports Suggest HIV Cure Is Near
New HIV Drug Class Shows Promise
Gene Therapy Shows Promise in Controlling HIV
Potential Microbicide Tricks HIV Into Sudden Death
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

July 2, 2013

World Health Organization Recommends Earlier HIV Treatment

The World Health Organization (WHO) has revised its treatment guidelines for people living with HIV worldwide, recommending they begin antiretroviral (ARV) therapy when their CD4 count hits 500 or below, as opposed to the previous benchmark of 350, The New York Times reports. WHO released the new guidelines on the opening day of the International AIDS Society 2013 conference in Kuala Lumpur.  

WHO also recommended that various subgroups of HIV-positive people receive ARVs regardless of CD4 count, including all children younger than 5, all pregnant and nursing women, and anyone in an ongoing relationship with an HIV-negative partner. The agency continues to advise that all of those who are HIV positive and living with active tuberculosis (TB) or with hepatitis B virus (HBV) receive ARVs.

A further recommendation is that all adults should begin treatment with a once-a-day, single pill combination therapy containing Viread (tenofovir), Sustiva (efavirenz) and either Epivir (lamivudine) or Emtriva (emtricitabine). (Atripla contains tenofovir, efavirenz and emtricitabine; a generic-based version of the combo uses lamivudine instead of emtricitabine—the two meds operate similarly—and has received tentative approval by the FDA.)

The new guidelines will extend drug eligibility from the current 17 million to 26 million people in poor and middle-income countries. WHO estimates that nearly 10 million people are currently receiving ARVs worldwide, out of a total 34 million living with the virus.

WHO projects that the new guidelines could prevent an additional 3 million deaths as well as 3.5 million new infections by 2025.

To read the Times story, click here.

To read the WHO release, click here.

Search: HIV treatment, antiretrovirals, World Health Organization, WHO, International AIDS Society 2013 conference, tuberculosis, TB, hepatitis B virus, HBV, Viread, tenofovir, Sustiva, efavirenz, Epivir, lamivudine, Emtriva, emtricitabine, Atripla.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    chrisf
    san jose
    California


    oceanblue65
    louisiana
    Louisiana


    jimmy807
    San Antonio
    Texas


    josebos
    KISSIMMEE
    Florida
Click here to join POZ Personals!
Conference Coverage

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


20th Conference on Retroviruses and Opportunistic Infections
(CROI 2013)
Atlanta, GA
March 3 - 7, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.